Knee pain becomes worse with age. Knee pain among the young population is associated with the
overuse of knee joints due to physical activity or sports. It is caused in the elderly population owing to
the wear and tear of the knee joint because of osteoarthritis and rheumatoid arthritis. Other causes of
knee pain include damaged menisci, tendinitis, pseudo gout, bursitis, high body weight, and others.
According to Market study report, Global demand for knee pain management is driven by increase in the
number of sports injuries, aging population, and rise in patient pool across the world. Rise in demand for
treatment options for knee pain is also boosting the global market. Surge in arthritis cases due to
lifestyle changes is expected to propel the global knee pain management market. Technological
advancements in joint replacement is a major factor likely to create lucrative opportunities in the global
knee pain management market during the forecast period. High prevalence and incidence of
osteoarthritis and rheumatoid arthritis among the adult and geriatric populations boosts the growth of
the global knee pain management market.
Knee Pain Management Market Covers the Table of Contents With Segments, Key Players And Region.
Based on Product Type, Knee Pain Management Market is sub segmented into Acute Knee pain and
Chronic Knee Pain. On the Basis of Application, Market is sub segmented into Hospitals Pharmacies,
Retail Pharmacies and drug stores, E-commerce.
Major Players profiled in the Knee Pain Management Market report incorporate: Ferring, Johnson &
Johnson, Amgen, Pfizer, Merck, F. Hoffmann-La Roche
Top Industry for Knee Pain Management Market News
1 Amgen
Amgen (NASDAQ: AMGN) today announced that EVENITY™ (romosozumab-aqqg) is now available for
shipment to wholesalers in the U.S. EVENITY was approved by the U.S. Food and Drug Administration
(FDA) on April 9, 2019, for the treatment of osteoporosis in postmenopausal women at high risk for
fracture.
"Osteoporosis is a silent disease that can lead to devastating consequences. Unfortunately, only 20
percent of women who have experienced a fracture receive any type of osteoporosis treatment post-
fracture," said Murdo Gordon, executive vice president of Global Commercial Operations at Amgen.
"This is unacceptable for the millions of women who have suffered from an osteoporosis-related
fracture. We need to urgently make postmenopausal osteoporosis a women's health priority."
2 Pfizer
Pfizer Inc and Eli Lilly and Company today announced top-line results from a Phase 3 study evaluating
tanezumab 2.5 mg and 5 mg. The objective of the study was to compare the long-term joint safety and
16-week efficacy of tanezumab relative to nonsteroidal anti-inflammatory drugs (NSAIDs) in patients
with moderate-to-severe osteoarthritis (OA) of the hip or knee. The tanezumab 5 mg treatment arm met
two of the three co-primary efficacy endpoints, demonstrating a statistically significant improvement in